At the recent 2023 ASCO GI Cancers Symposium, researchers from the Royal College of Surgeons in Ireland (RCSI) presented results of a preclinical study that aimed to evaluate the potential of administering the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor ribociclib with the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib.
Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's disease, hepatic fibrosis, viral infections, inflammatory disorders and polycystic kidney.
LG Chem has described urea derivatives acting as macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
TANK-binding kinase 1 (TBK1) is a multifunctional serine/threonine kinase with an established role coordinating innate immune responses, and it has been previously identified as a candidate immune evasion gene. Additionally, disrupting TBK1 signaling has shown potential for enhancing response to immunotherapy with immune checkpoint blockade (ICB) in murine tumor models.
Polymeric nanoparticles selectively accumulate in solid tumors in part due to tumor-associated angiogenesis without efficient lymphatic drainage exerting an enhanced permeation and retention (EPR) effect. Many radiotherapies fail due to poor tumor cell selectivity.
Mirati Therapeutics Inc. has received FDA clearance of its IND application for MRTX-1133, a potent, oral small-molecule inhibitor of the KRAS G12D driver mutation.
Researchers from Guangzhou Institutes of Biomedicine and Health and CSIRO presented the discovery and preclinical characterization of novel compounds with high activity against androgen receptor (AR)-dependent prostate cancer cells.
The discovery of two new sarcoma-specific pathways and 14 new genes that predispose people to heritable sarcomas could pave the way to managing cancer risk early via detection of these mutations for this rare type of cancer. Sarcomas are rare connective tissue malignancies mostly derived from embryonic mesoderm and affect younger people.
RSS
